Lipella Pharmaceuticals Common Net Income
| LIPO Stock | 0.19 0.02 11.76% |
As of the 9th of February, Lipella Pharmaceuticals secures the Standard Deviation of 13.47, mean deviation of 8.28, and Risk Adjusted Performance of (0.02). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lipella Pharmaceuticals, as well as the relationship between them.
Lipella Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.1499 | Revenue | Earnings Share (3.33) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -2.3 M | -2.2 M | |
| Net Loss | -4.5 M | -4.3 M | |
| Net Loss | -4.5 M | -4.3 M | |
| Net Loss | (5.50) | (5.78) |
Lipella | Net Income | Build AI portfolio with Lipella Stock |
Evaluating Lipella Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lipella Pharmaceuticals Common's fundamental strength.
Latest Lipella Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Lipella Pharmaceuticals Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lipella Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Lipella Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lipella Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipella Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.02 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Lipella Net Income Regression Statistics
| Arithmetic Mean | (1,387,181) | |
| Coefficient Of Variation | (142.86) | |
| Mean Deviation | 1,715,159 | |
| Median | (61,848) | |
| Standard Deviation | 1,981,664 | |
| Sample Variance | 3.9T | |
| Range | 5M | |
| R-Value | (0.83) | |
| Mean Square Error | 1.3T | |
| R-Squared | 0.69 | |
| Significance | 0.000036 | |
| Slope | (326,108) | |
| Total Sum of Squares | 62.8T |
Lipella Net Income History
Other Fundumenentals of Lipella Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Lipella Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lipella Pharmaceuticals is extremely important. It helps to project a fair market value of Lipella Stock properly, considering its historical fundamentals such as Net Income. Since Lipella Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lipella Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lipella Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Lipella Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lipella Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lipella Pharmaceuticals.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Lipella Pharmaceuticals on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Lipella Pharmaceuticals Common or generate 0.0% return on investment in Lipella Pharmaceuticals over 90 days. Lipella Pharmaceuticals is related to or competes with Protagenic Therapeutics, GT Biopharma, Azitra, Artelo Biosciences, Dermata Therapeutics, Virax Biolabs, and Indaptus Therapeutics. Lipella Pharmaceuticals is entity of United States More
Lipella Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lipella Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lipella Pharmaceuticals Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 94.73 | |||
| Value At Risk | (21.74) | |||
| Potential Upside | 17.14 |
Lipella Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipella Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lipella Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Lipella Pharmaceuticals historical prices to predict the future Lipella Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.64) | |||
| Total Risk Alpha | (1.84) | |||
| Treynor Ratio | (0.31) |
Lipella Pharmaceuticals February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 8.28 | |||
| Coefficient Of Variation | (2,697) | |||
| Standard Deviation | 13.47 | |||
| Variance | 181.31 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.64) | |||
| Total Risk Alpha | (1.84) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 94.73 | |||
| Value At Risk | (21.74) | |||
| Potential Upside | 17.14 | |||
| Skewness | 2.13 | |||
| Kurtosis | 11.07 |
Lipella Pharmaceuticals Backtested Returns
Lipella Pharmaceuticals has Sharpe Ratio of -0.0526, which conveys that the firm had a -0.0526 % return per unit of risk over the last 3 months. Lipella Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lipella Pharmaceuticals' Mean Deviation of 8.28, risk adjusted performance of (0.02), and Standard Deviation of 13.47 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.65, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lipella Pharmaceuticals will likely underperform. At this point, Lipella Pharmaceuticals has a negative expected return of -0.71%. Please make sure to verify Lipella Pharmaceuticals' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Lipella Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.24 |
Weak reverse predictability
Lipella Pharmaceuticals Common has weak reverse predictability. Overlapping area represents the amount of predictability between Lipella Pharmaceuticals time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lipella Pharmaceuticals price movement. The serial correlation of -0.24 indicates that over 24.0% of current Lipella Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.24 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Lipella Pharmaceuticals Common reported net income of (5.02 Million). This is 101.47% lower than that of the Biotechnology sector and 107.16% lower than that of the Health Care industry. The net income for all United States stocks is 100.88% higher than that of the company.
Lipella Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipella Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipella Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lipella Pharmaceuticals by comparing valuation metrics of similar companies.Lipella Pharmaceuticals is currently under evaluation in net income category among its peers.
Lipella Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Lipella Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Lipella Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lipella Pharmaceuticals' value.| Shares | Tower Research Capital Llc | 2025-06-30 | 0.0 | Mccormack Advisors International | 2025-06-30 | 0.0 | Virtu Financial Llc | 2025-03-31 | 0.0 | Bank Of America Corp | 2025-06-30 | 0.0 |
Lipella Fundamentals
| Return On Equity | -2.48 | ||||
| Return On Asset | -1.18 | ||||
| Operating Margin | (15.64) % | ||||
| Current Valuation | (710.26 K) | ||||
| Shares Outstanding | 4.62 M | ||||
| Shares Owned By Insiders | 6.52 % | ||||
| Shares Owned By Institutions | 1.30 % | ||||
| Number Of Shares Shorted | 100.09 K | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 2.96 X | ||||
| Revenue | 536.36 K | ||||
| Gross Profit | (3.42 M) | ||||
| EBITDA | (5.01 M) | ||||
| Net Income | (5.02 M) | ||||
| Total Debt | 47.6 K | ||||
| Book Value Per Share | 0.61 X | ||||
| Cash Flow From Operations | (3.95 M) | ||||
| Short Ratio | 3.32 X | ||||
| Earnings Per Share | (3.33) X | ||||
| Target Price | 10.0 | ||||
| Beta | -0.077 | ||||
| Market Capitalization | 2.45 M | ||||
| Total Asset | 2.67 M | ||||
| Retained Earnings | (15.34 M) | ||||
| Working Capital | 1.86 M | ||||
| Net Asset | 2.67 M |
About Lipella Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipella Pharmaceuticals Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipella Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipella Pharmaceuticals Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipella Stock
Moving against Lipella Stock
| 0.88 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.79 | DSGN | Design Therapeutics | PairCorr |
| 0.63 | ENGN | enGene Holdings Common | PairCorr |
| 0.59 | 63E | ONWARD MEDICAL BV | PairCorr |
| 0.59 | KYTX | Kyverna Therapeutics | PairCorr |
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.